Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
BMC Cancer
    July 2024
  1. MOHAMED AH, Mohamed KA, Kayacan E, Nur Y, et al
    Clinical characteristics and factors associated with survival rate of patients with non-muscle invasive bladder cancer attending at a Tertiary Hospital in Somalia.
    BMC Cancer. 2024;24:839.
    >> Share

    June 2024
  2. ZHANG X, Hong B, Li H, Zhao J, et al
    Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.
    BMC Cancer. 2024;24:746.
    >> Share

  3. MENG H, Yang R, Lin Q, Du W, et al
    Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b.
    BMC Cancer. 2024;24:737.
    >> Share

  4. JI J, Zhang T, Zhu L, Yao Y, et al
    Using machine learning to develop preoperative model for lymph node metastasis in patients with bladder urothelial carcinoma.
    BMC Cancer. 2024;24:725.
    >> Share

    March 2024
  5. LI X, Liang Z, Pan J, Zhang M, et al
    Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.
    BMC Cancer. 2024;24:328.
    >> Share

    February 2024
  6. HUANG LH, Chen CS, Li JR, Chiu KY, et al
    The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.
    BMC Cancer. 2024;24:247.
    >> Share

  7. ZHANG J, Yang M, Wei D, Zhang D, et al
    The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
    BMC Cancer. 2024;24:202.
    >> Share

  8. YANG M, Zhang J, Wei D, Yu T, et al
    Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
    BMC Cancer. 2024;24:196.
    >> Share

    January 2024
  9. PAN DL, Zhang LF, Li XJ, Zhang KP, et al
    Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:159.
    >> Share

  10. VERGHOTE F, Van Praet C, Berquin C, Lumen N, et al
    Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice.
    BMC Cancer. 2024;24:160.
    >> Share

  11. JING S, Yang E, Luo Z, Zhang Y, et al
    Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer.
    BMC Cancer. 2024;24:127.
    >> Share

    November 2023
  12. GORE JL, Wolff EM, Comstock BA, Follmer KM, et al
    Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    BMC Cancer. 2023;23:1127.
    >> Share

  13. ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
    BMC Cancer. 2023;23:1080.
    >> Share

  14. LU L, Chen C, Cheng H, Ding H, et al
    Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1066.
    >> Share

    October 2023
  15. CHEN JX, Huang WT, Zhang QY, Deng CE, et al
    The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:1018.
    >> Share

  16. LI Y, Xu K, Zhang Y, Mao H, et al
    Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    BMC Cancer. 2023;23:1021.
    >> Share

  17. LUO L, Xie Q, Wu Y, Li P, et al
    Circular RNA CCT3 is a unique molecular marker in bladder cancer.
    BMC Cancer. 2023;23:977.
    >> Share

  18. HE Q, Wu S, Zhou Y, Liu Y, et al
    Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder cancer.
    BMC Cancer. 2023;23:965.
    >> Share

  19. ZHENHAI Z, Qi C, Shuchao Z, Zhongqi W, et al
    MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.
    BMC Cancer. 2023;23:956.
    >> Share

  20. TANABE K, Nakanishi Y, Okubo N, Matsumoto S, et al
    Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
    BMC Cancer. 2023;23:940.
    >> Share

  21. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    >> Share

    September 2023
  22. ALT M, Stecca C, Lin Y, Kazeem G, et al
    Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
    BMC Cancer. 2023;23:919.
    >> Share

  23. TSAI TH, Su PJ, Huang SY, Kuo MC, et al
    The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
    BMC Cancer. 2023;23:871.
    >> Share

  24. NASR S, Haddad FG, Khazen J, Kattan J, et al
    PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience.
    BMC Cancer. 2023;23:817.
    >> Share

    August 2023
  25. CAI Y, Cheng Y, Wang Z, Li L, et al
    A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    BMC Cancer. 2023;23:725.
    >> Share

  26. JIANG Y, Zhu C, Huang H, Huang G, et al
    TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
    BMC Cancer. 2023;23:716.
    >> Share

    July 2023
  27. LI W, Liu Z, Jin K, Shao F, et al
    Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:661.
    >> Share

    June 2023
  28. KERZELI IK, Kostakis A, Turker P, Malmstrom PU, et al
    Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
    BMC Cancer. 2023;23:605.
    >> Share

  29. LIANG PI, Lai HY, Chan TC, Li WM, et al
    Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
    BMC Cancer. 2023;23:599.
    >> Share

  30. LIU J, Wu P, Lai S, Wang J, et al
    Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
    BMC Cancer. 2023;23:574.
    >> Share

  31. NISHIYAMA H, Tanaka Y, Hamada M, Ozaki M, et al
    Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
    BMC Cancer. 2023;23:565.
    >> Share

  32. RUTTEN VC, Salhi Y, Robbrecht GJ, de Wit R, et al
    The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.
    BMC Cancer. 2023;23:539.
    >> Share

  33. KOLL FJ, Doring C, Olah C, Szarvas T, et al
    Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
    BMC Cancer. 2023;23:504.
    >> Share

    April 2023
  34. HUI P, Ni F, Zheng L, Jia L, et al
    Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
    BMC Cancer. 2023;23:355.
    >> Share

  35. TANG Y, Lei Y, Gao P, Jia J, et al
    Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker.
    BMC Cancer. 2023;23:328.
    >> Share

  36. YANG X, Zhang S, Cui Y, Li Y, et al
    Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
    BMC Cancer. 2023;23:320.
    >> Share

    February 2023
  37. HUANG W, Zhu L, Huang H, Li Y, et al
    IGF2BP3 overexpression predicts poor prognosis and correlates with immune infiltration in bladder cancer.
    BMC Cancer. 2023;23:116.
    >> Share

  38. JUNG M, Rose M, Knuechel R, Loeffler C, et al
    Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
    BMC Cancer. 2023;23:113.
    >> Share

    December 2022
  39. MOLLER CT, Stoer NC, Blindheim A, Berge V, et al
    Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study.
    BMC Cancer. 2022;22:1301.
    >> Share

    November 2022
  40. COQUAN E, Clarisse B, Lequesne J, Brachet PE, et al
    TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
    BMC Cancer. 2022;22:1213.
    >> Share

  41. OH TJ, Lim E, Bang BR, Lee JJ, et al
    Identification and validation of methylated PENK gene for early detection of bladder cancer using urine DNA.
    BMC Cancer. 2022;22:1195.
    >> Share

  42. HUANG Q, Zi H, Luo L, Li X, et al
    Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030.
    BMC Cancer. 2022;22:1164.
    >> Share

  43. HU J, Wang L, Li L, Wang Y, et al
    A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    BMC Cancer. 2022;22:1158.
    >> Share

    September 2022
  44. XIONG M, Li W, Wang L, Chen L, et al
    Comprehensive analysis of alternative polyadenylation regulators concerning CD276 and immune infiltration in bladder cancer.
    BMC Cancer. 2022;22:1026.
    >> Share

  45. GAO L, Ren R, Shen J, Hou J, et al
    Values of OAS gene family in the expression signature, immune cell infiltration and prognosis of human bladder cancer.
    BMC Cancer. 2022;22:1016.
    >> Share

    August 2022
  46. XING P, Jiang Z, Liu Y
    Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
    BMC Cancer. 2022;22:926.
    >> Share

    July 2022
  47. LIN Q, Pei L, Zhao Z, Zhuang X, et al
    Glycoprotein alpha-Subunit of Glucosidase II (GIIalpha) is a novel prognostic biomarker correlated with unfavorable outcome of urothelial carcinoma.
    BMC Cancer. 2022;22:817.
    >> Share

  48. MIYAI K, Kawamura K, Ito K, Matsukuma S, et al
    Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma.
    BMC Cancer. 2022;22:787.
    >> Share

  49. KIM GT, Kim EY, Shin SH, Lee H, et al
    Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma.
    BMC Cancer. 2022;22:727.
    >> Share

    June 2022
  50. HOU J, Lu Z, Cheng X, Dong R, et al
    Ferroptosis-related long non-coding RNA signature predicts the prognosis of bladder cancer.
    BMC Cancer. 2022;22:719.
    >> Share

  51. LI JD, Farah AA, Huang ZG, Zhai GQ, et al
    Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
    BMC Cancer. 2022;22:713.
    >> Share

  52. ZHANG Q, Zhang W, Lin T, Lu W, et al
    Mass cytometry reveals immune atlas of urothelial carcinoma.
    BMC Cancer. 2022;22:677.
    >> Share

  53. JIANG L, Chen S, Pan Q, Zheng J, et al
    The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.
    BMC Cancer. 2022;22:676.
    >> Share

  54. JEONG SH, Han JH, Jeong CW, Kim HH, et al
    Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor.
    BMC Cancer. 2022;22:631.
    >> Share

    May 2022
  55. HAO N, Yang D, Liu T, Liu S, et al
    Laminin-integrin a6b4 interaction activates notch signaling to facilitate bladder cancer development.
    BMC Cancer. 2022;22:558.
    >> Share

  56. ZHU L, Liu X, Zhang W, Hu H, et al
    MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.
    BMC Cancer. 2022;22:556.
    >> Share

  57. DENG L, Chao H, Deng H, Yu Z, et al
    A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer.
    BMC Cancer. 2022;22:510.
    >> Share

  58. WEICKHARDT AJ, Lau DK, Hodgson-Garms M, Lavis A, et al
    Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    BMC Cancer. 2022;22:478.
    >> Share

    April 2022
  59. YANG Z, Zhang X, Zhang J, Gao J, et al
    Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT
    BMC Cancer. 2022;22:462.
    >> Share

  60. FANG C, Huang X, Dai J, He W, et al
    The circular RNA circFARSA sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.
    BMC Cancer. 2022;22:373.
    >> Share

    March 2022
  61. WU Z, Xia C, Zhang C, Yang D, et al
    Prognostic significance of SNCA and its methylation in bladder cancer.
    BMC Cancer. 2022;22:330.
    >> Share

  62. BHATTACHARJEE S, Sullivan MJ, Wynn RR, Demagall A, et al
    PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth.
    BMC Cancer. 2022;22:312.
    >> Share

  63. SUN M, Liu X, Zhao W, Zhang B, et al
    Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p.
    BMC Cancer. 2022;22:313.
    >> Share

  64. GUAN Z, Sun Y, Mu L, Jiang Y, et al
    Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF-kappaB signaling activation.
    BMC Cancer. 2022;22:240.
    >> Share

  65. FANG Q, Zhang X, Nie Q, Hu J, et al
    Improved urine DNA methylation panel for early bladder cancer detection.
    BMC Cancer. 2022;22:237.
    >> Share

    February 2022
  66. WANG R, Kang H, Zhang X, Nie Q, et al
    Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
    BMC Cancer. 2022;22:214.
    >> Share

  67. KIM KS, Kim SH, Cho HJ, Sur HJ, et al
    Holmium laser-assisted laparoscopic partial cystectomy for bladder cancer: a single-institutional pilot study with technical feasibility and short-term oncological outcome.
    BMC Cancer. 2022;22:195.
    >> Share

  68. WAHLIN S, Boman K, Moran B, Nodin B, et al
    Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
    BMC Cancer. 2022;22:131.
    >> Share

    January 2022
  69. HUANG T, Li J, Wang SM
    Core promoter mutation contributes to abnormal gene expression in bladder cancer.
    BMC Cancer. 2022;22:68.
    >> Share

  70. ZHANG Y, Zhu B, Cai Y, Zhu S, et al
    Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration.
    BMC Cancer. 2022;22:2.
    >> Share

    December 2021
  71. LIN H, Shi X, Li H, Hui J, et al
    Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer.
    BMC Cancer. 2021;21:1293.
    >> Share

  72. MARTINEZ CHANZA N, Soukane L, Barthelemy P, Carnot A, et al
    Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
    BMC Cancer. 2021;21:1292.
    >> Share

    November 2021
  73. SMITH V, Mukherjee D, Lunj S, Choudhury A, et al
    The effect of hypoxia on PD-L1 expression in bladder cancer.
    BMC Cancer. 2021;21:1271.
    >> Share

  74. LI X, Fu S, Huang Y, Luan T, et al
    Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer.
    BMC Cancer. 2021;21:1267.
    >> Share

  75. MA T, Wang X, Meng L, Liu X, et al
    An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    BMC Cancer. 2021;21:1256.
    >> Share

  76. FUKUHARA H, Nohara T, Nishimoto K, Hatakeyama Y, et al
    Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study.
    BMC Cancer. 2021;21:1223.
    >> Share

    October 2021
  77. HINSENVELD FJ, Noordman BJ, Boormans JL, Voortman J, et al
    Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    BMC Cancer. 2021;21:1161.
    >> Share

  78. ZHEN H, Du P, Yi Q, Tang X, et al
    LINC00958 promotes bladder cancer carcinogenesis by targeting miR-490-3p and AURKA.
    BMC Cancer. 2021;21:1145.
    >> Share

  79. VERGHOTE F, Poppe L, Verbeke S, Dirix P, et al
    Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    BMC Cancer. 2021;21:1113.
    >> Share

    September 2021
  80. WANG M, Ren X, Wang G, Sun X, et al
    Construction of a survival prediction model for high-and low -grade UTUC after tumor resection based on "SEER database": a multicenter study.
    BMC Cancer. 2021;21:999.
    >> Share

  81. COLLING R, Colling H, Browning L, Verrill C, et al
    Validation of grading of non-invasive urothelial carcinoma by digital pathology for routine diagnosis.
    BMC Cancer. 2021;21:995.
    >> Share

    August 2021
  82. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Correction to: Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:956.
    >> Share

  83. LIANG Y, Ye F, Xu C, Zou L, et al
    A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:943.
    >> Share

  84. WANG X, Guo J, Wang L, Wang M, et al
    Modified completely intrafascial radical cysprostatectomy for bladder cancer: a single-center, blinded, controlled study.
    BMC Cancer. 2021;21:887.
    >> Share

    July 2021
  85. LI J, Cao J, Li P, Yao Z, et al
    Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    BMC Cancer. 2021;21:858.
    >> Share

  86. TANG X, Qian WL, Yan WF, Pang T, et al
    Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.
    BMC Cancer. 2021;21:823.
    >> Share

  87. FU Y, Sun S, Bi J, Kong C, et al
    A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:810.
    >> Share

    June 2021
  88. WANG Z, Tu L, Chen M, Tong S, et al
    Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    BMC Cancer. 2021;21:692.
    >> Share

  89. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:676.
    >> Share

    May 2021
  90. LYU X, Wang P, Qiao Q, Jiang Y, et al
    Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    BMC Cancer. 2021;21:646.
    >> Share

  91. CHEN X, Lin X, Pang G, Deng J, et al
    Significance of KDM6A mutation in bladder cancer immune escape.
    BMC Cancer. 2021;21:635.
    >> Share

  92. CHAN LC, Kalyanasundram J, Leong SW, Masarudin MJ, et al
    Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes.
    BMC Cancer. 2021;21:625.
    >> Share

  93. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor.
    BMC Cancer. 2021;21:604.
    >> Share

  94. GRIVAS P, Loriot Y, Morales-Barrera R, Teo MY, et al
    Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
    BMC Cancer. 2021;21:593.
    >> Share

  95. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    >> Share

    April 2021
  96. ZHANG Z, Yu Y, Zhang P, Ma G, et al
    Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    BMC Cancer. 2021;21:458.
    >> Share

  97. MANZANO RG, Catalan-Latorre A, Brugarolas A
    RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    BMC Cancer. 2021;21:432.
    >> Share

    March 2021
  98. MIYAKE M, Iida K, Nishimura N, Miyamoto T, et al
    Non-maintenance intravesical Bacillus Calmette-Guerin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
    BMC Cancer. 2021;21:266.
    >> Share

  99. CHEN F, Wang Q, Zhou Y
    The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
    BMC Cancer. 2021;21:244.
    >> Share

    February 2021
  100. YANG B, Zhao X, Wan C, Ma X, et al
    Genomic profiling of Chinese patients with urothelial carcinoma.
    BMC Cancer. 2021;21:162.
    >> Share

    January 2021
  101. YONEYAMA T, Hatakeyama S, Sutoh Yoneyama M, Yoshiya T, et al
    Tumor vasculature-targeted (10)B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy.
    BMC Cancer. 2021;21:72.
    >> Share

  102. PORRECA A, Palmer K, Artibani W, Antonelli A, et al
    Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer.
    BMC Cancer. 2021;21:51.
    >> Share

  103. OKAMURA S, Yoshino H, Kuroshima K, Tsuruda M, et al
    EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
    BMC Cancer. 2021;21:48.
    >> Share

    December 2020
  104. KIM TM, Yoo JS, Moon HW, Hur KJ, et al
    Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up.
    BMC Cancer. 2020;20:1203.
    >> Share

  105. JOHN A, Gunes C, Bolenz C, Vidal-Y-Sy S, et al
    Bladder cancer-derived interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface.
    BMC Cancer. 2020;20:1178.
    >> Share

    November 2020
  106. ZHAI M, Tang C, Li M, Chen X, et al
    Short-term mortality risks among patients with non-metastatic bladder cancer.
    BMC Cancer. 2020;20:1148.
    >> Share

    October 2020
  107. LIU B, Sun W, Gao W, Li L, et al
    microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis.
    BMC Cancer. 2020;20:1019.
    >> Share

    September 2020
  108. KOTECHA P, Moss CL, Enting D, Gillett C, et al
    Cohort profile: King's Health Partners bladder cancer biobank.
    BMC Cancer. 2020;20:920.
    >> Share

  109. TIAN Z, Meng L, Wang X, Diao T, et al
    Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma.
    BMC Cancer. 2020;20:851.
    >> Share

    August 2020
  110. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    >> Share

    June 2020
  111. MAKELA R, Arjonen A, Harma V, Rintanen N, et al
    Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
    BMC Cancer. 2020;20:590.
    >> Share

    March 2020
  112. PARKER HG, Dhawan D, Harris AC, Ramos-Vara JA, et al
    RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors.
    BMC Cancer. 2020;20:251.
    >> Share

    February 2020
  113. HUPE MC, Dormayer L, Ozimek T, Struck JP, et al
    Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer.
    BMC Cancer. 2020;20:140.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016